Life Sciences

  • January 22, 2026

    House Report Claims Evidence of CVS Antitrust Violations

    House Judiciary Committee staffers said Wednesday that they'd uncovered "a pattern of anticompetitive activity" in CVS Health tactics aimed at coercing independent pharmacies into avoiding working with online services the company saw as a threat to its own pharmacy and pharmacy benefit manager businesses.

  • January 22, 2026

    Supplement Cos. Challenge FDA Health Claim Denials

    A group of health supplement companies hit the U.S. Food and Drug Administration with a suit in D.C. federal court Wednesday alleging regulators wrongly denied them approval to make over 100 distinct claims concerning the health benefits of their products.

  • January 22, 2026

    Merck Can't Get Fed. Circ. To Reconsider Axing MS Drug Patents

    The Federal Circuit on Thursday refused to reconsider decisions invalidating Merck KGaA patents on the blockbuster multiple sclerosis drug Mavenclad, turning aside the German drugmaker's claim that the court set an unjust new rule that means inventors' work can later be used against them.

  • January 22, 2026

    Hologic Faces Del. Class Suit Over $18.3B Sale Disclosures

    Citing alleged failures to make news about litigation settlements public ahead of a proposed $18.3 billion company sale, a pension fund stockholder of women's health-focused tech company Hologic Inc. has sued for a Delaware Court of Chancery hold on the deal pending disclosures or damages awards.

  • January 22, 2026

    3rd Circ. Says Medical Pot Contract May Violate Federal Law

    The Third Circuit on Thursday vacated a medical cannabis company's win in a lawsuit filed by a consultant claiming that it had stolen his trade secrets for growing marijuana samples, finding it couldn't decide the appeal because the parties' contract might have violated federal drug law.

  • January 22, 2026

    AI Diagnostics Co.'s Patent Claims Don't Pass Alice Test

    A California federal judge has thrown out artificial intelligence diagnostics company Tempus AI's patent infringement suit against medical test-maker Guardant Health, finding claims in the patents weren't patent-eligible to begin with.

  • January 22, 2026

    Simpson Thacher Adds Quinn Emanuel Atty To New SF Office

    A Quinn Emanuel Urquhart & Sullivan LLP attorney who worked on high-profile intellectual property matters representing Google and Jane Street Group has joined Simpson Thacher & Bartlett LLP as partner in its newly opened San Francisco office, the firm announced Thursday.

  • January 22, 2026

    Medical Cannabis Co. Says Data Breach Didn't Lead To Injury

    An Ohio medical cannabis company has said a consolidated class action in federal court should be dismissed as it doesn't allege any of the plaintiffs' data was accessed in a data breach or that the breach could be linked to any real damage.

  • January 22, 2026

    Investors Drop LA Law Firm From Bioscience Fraud Suit

    A group of investors including a "Toy Story" screenwriter pursuing an $87 million fraud suit against a bioscience company in California state court has agreed to drop claims against a California law firm and its name partner, with the firm in turn withdrawing an anti-SLAPP motion it filed in the suit.

  • January 21, 2026

    Holmes Seeks Trump Clemency For Theranos Fraud Sentence

    Former Theranos CEO Elizabeth Holmes has asked President Donald Trump to commute an 11-year prison sentence she's been serving for defrauding investors with bogus blood-testing technology, according to the U.S. Department of Justice's Office of the Pardon Attorney.

  • January 21, 2026

    CVS, UnitedHealth, Express Scripts Duck PBM Antitrust Suit

    A Missouri federal judge has thrown out a proposed class action accusing the country's three largest pharmacy benefit managers — owned by CVS, UnitedHealth Group and Cigna Group — of inflating prescription costs through their rebating practices.

  • January 21, 2026

    Bristol-Myers' Worker Arbitration Push Scrutinized On Appeal

    A Washington Court of Appeals panel expressed reluctance to award Bristol-Myers Squibb Co.'s bid to send a former worker's age discrimination case to arbitration Wednesday, while also casting some doubt on the ex-employee's stance that the arbitration pact she signed was invalid.

  • January 21, 2026

    Medtronic 'Blocked' Surgical Device Competition, Jury Told

    An executive at Applied Medical Resources Corp. on Tuesday told a California federal jury considering antitrust claims against Medtronic Inc. that a surgical device his company introduced a decade ago had great success in Europe but was "blocked" in the U.S. by Medtronic's practice of "bundling" products.

  • January 21, 2026

    Texas AG Launches Investigation Into Vaccine Incentives

    The Texas attorney general launched what it characterized as a sweeping, multi-industry investigation into financial incentives for medical providers to recommend childhood vaccines, saying providers regularly dish out vaccines that "are not proven to be safe or necessary."

  • January 21, 2026

    Novartis Gets Win On Entresto Patent Tied To Earlier Ruling

    A Delaware federal judge found Wednesday that MSN Pharmaceuticals Inc. infringed a patent covering Novartis Pharmaceuticals Corp.'s blockbuster cardiovascular drug Entresto, saying the issue has already been litigated before.

  • January 21, 2026

    Allergan Says Fed. Circ.'s Ax Of $39M Win Misread Record

    A Federal Circuit decision reversing a $39 million verdict against Sandoz in Allergan's suit accusing it of infringing an eyelash growth drug patent misunderstood the evidence and was based on an "indisputably false" premise, Allergan said in a petition for rehearing Tuesday.

  • January 21, 2026

    Teva's Inconsistent Args In IUD Trial 'Troubling,' Judge Says

    Teva Pharmaceuticals quickly ran afoul of a Georgia federal judge Wednesday in its first trial over alleged defects in its Paragard IUD, as the court chastised the drugmaker's attorneys over "very troubling" inconsistencies in their opening statements to jurors.

  • January 21, 2026

    FTC Mulling Deal With Express Scripts In PBM Case

    The Federal Trade Commission is considering a potential settlement with Express Scripts in the agency's case accusing the country's three largest pharmacy benefit managers of inflating insulin prices through rebate schemes.

  • January 21, 2026

    Fla. Dispensary Exposed Patient Data Via Google, Suit Says

    A Florida man is suing a dispensary website in federal court, alleging it has violated federal health confidentiality laws by using Google Analytics Pixel on its website, which he said intercepts and collects private information for use in advertising.

  • January 20, 2026

    Justices To Clarify What's Fair Game With 'Skinny Labels'

    A new U.S. Supreme Court patent case that will require the justices to spell out what generic-drug makers can say when marketing drugs with so-called skinny labels will shape whether and how those companies use the tactic of carving out patented uses from labels, attorneys say.

  • January 20, 2026

    Orrick Expands IP Team With Cadwalader, Kirkland Litigators

    Orrick Herrington & Sutcliffe LLP has beefed up its intellectual property litigation team with three new partners experienced in counseling technology and life sciences clients, adding two former Cadwalader Wickersham & Taft LLP litigators in New York and a former Kirkland & Ellis LLP partner in Los Angeles.

  • January 20, 2026

    Dentsply Can't Shed Investors' Aligner Injury Cover-Up Suit

    Dental supply company Dentsply Sirona Inc. must face a proposed investor class action alleging it covered up medical injuries and other issues affecting an aligner business it acquired for $1 billion, and caused shareholder losses when the injuries were revealed and the acquisition collapsed.

  • January 20, 2026

    Law360 Names Firms Of The Year

    Eight law firms have earned spots as Law360's Firms of the Year, with 48 Practice Group of the Year awards among them, achieving milestones such as high-profile litigation wins at the U.S. Supreme Court and 11-figure merger deals.

  • January 20, 2026

    Fed. Circ. Revives Inventor's Spinal Patent Case Against DePuy

    The Federal Circuit on Tuesday revived an inventor's patent infringement suit against DePuy Synthes Cos., ruling that the persuasiveness of expert testimony that was excluded by a lower court is best left for the jury.

  • January 20, 2026

    Philips CPAP Cancer Suit Sent Back To Kentucky

    A Pennsylvania federal judge has sent back to state court a suit in the multidistrict litigation over recalled CPAP devices brought against Philips RS North America by a Kentucky woman who claims her sleep apnea machine caused her cancer, finding that a middleman supplier wasn't added to thwart federal jurisdiction.

Expert Analysis

  • Series

    Preaching Makes Me A Better Lawyer

    Author Photo

    Becoming a Gospel preacher has enhanced my success as a trial lawyer by teaching me the importance of credibility, relatability, persuasiveness and thorough preparation for my congregants, the same skills needed with judges and juries in the courtroom, says Reginald Harris at Stinson.

  • A Look At Middlemen Fees In 340B Drug Discount Program

    Author Photo

    A U.S. Senate committee's recent hearing on the Section 340B drug discount program, along with statistical analysis of payment amounts, contribute to a growing consensus that middlemen fees are too high, say William Sarraille at the University of Maryland, and Shanyue Zeng and Rory Martin at IQVIA.

  • How Large Patent Damages Awards Actually Play Out

    Author Photo

    Most large verdicts in patent infringement cases are often overturned or reduced on appeal, implying that the Federal Circuit is serving its intended purpose of correcting outlier outcomes, and that the figures that catch headlines and dominate policy debates may misrepresent economic realities, says Bowman Heiden at Berkeley School of Law.

  • Series

    Law School's Missed Lessons: Practicing Client-Led Litigation

    Author Photo

    New litigators can better help their corporate clients achieve their overall objectives when they move beyond simply fighting for legal victory to a client-led approach that resolves the legal dispute while balancing the company's competing out-of-court priorities, says Chelsea Ireland at Cohen Ziffer.

  • Navigating 2025's Post-Grant Proceeding Shakeups

    Author Photo

    Extensive changes to the U.S. Patent Trial and Appeal Board's post-grant proceedings this year, including the new settled expectations factor and revitalization of Fintiv factors, require petitioners and patent owners alike to be mindful when selecting patents to assert and challenge, say attorneys at Quinn Emanuel.

  • Series

    The Law Firm Merger Diaries: How To Build On Cultural Fit

    Author Photo

    Law firm mergers should start with people, then move to strategy: A two-level screening that puts finding a cultural fit at the pinnacle of the process can unearth shared values that are instrumental to deciding to move forward with a combination, says Matthew Madsen at Harrison.

  • Latisse Ruling's Lessons On Avoiding Chemical Patent Pitfalls

    Author Photo

    The Federal Circuit's decision in Duke v. Sandoz, reversing a $39 million infringement claim for selling a generic Latisse product, reinforces a fundamental truth in chemical patent strategy: Broad genus claims rarely survive without clear evidence of possession of specific embodiments, says Kimberly Vines at Stites & Harbison.

  • Considerations When Invoking The Common-Interest Privilege

    Author Photo

    To successfully leverage the common-interest doctrine in a multiparty transaction or complex litigation, practitioners should be able to demonstrate that the parties intended for it to apply, that an underlying privilege like attorney-client has attached, and guard against disclosures that could waive privilege and defeat its purpose, say attorneys at DLA Piper.

  • Series

    The Law Firm Merger Diaries: Making The Case To Combine

    Author Photo

    When making the decision to merge, law firm leaders must factor in strategic alignment, cultural compatibility and leadership commitment in order to build a compelling case for combining firms to achieve shared goals and long-term success, says Kevin McLaughlin at UB Greensfelder.

  • Key Risks For Cos. As MAHA Influences Food Regulation

    Author Photo

    As the Make America Healthy Again movement alters state and federal legislative and regulatory priorities, measures targeting ultra-processed foods, front-of-package labeling requirements and restrictions on schools are creating new compliance and litigation risks for food and beverage manufacturers, pharmaceutical companies, retailers and digital advertisers, say attorneys at Kelley Drye.

  • State AGs May Extend Their Reach To Nat'l Security Concerns

    Author Photo

    Companies with foreign supply-chain risk exposure need a comprehensive risk-management strategy to address a growing trend in which state attorneys general use broadly written state laws to target conduct that may not violate federal regulations, but arguably constitutes a national security threat, say attorneys at Wiley.

  • Opinion

    Despite Deputy AG Remarks, DOJ Can't Sideline DC Bar

    Author Photo

    Deputy Attorney General Todd Blanche’s recent suggestion that the D.C. Bar would be prevented from reviewing misconduct complaints about U.S. Department of Justice attorneys runs contrary to federal statutes, local rules and decades of case law, and sends the troubling message that federal prosecutors are subject to different rules, say attorneys at HWG.

  • Key Strategies For Supplement Cos. Facing Lead Risks

    Author Photo

    In the wake of a recent Consumer Reports article detailing dangerously high levels of lead in many popular protein powders, supplement companies face increased litigation, rising enforcement risks and reputational harm — underscoring the need to monitor supply chains, test ingredients and understand labeling standards, say attorneys at Husch Blackwell.

  • From Bank Loans To Private Credit: Tips For Making The Shift

    Author Photo

    The relationship between private credit and syndicated bank deals will evolve as the private market continues to grow, introducing new challenges for borrowers comparing financing options, particularly pertaining to loan documentation and working capital, say attorneys at Haynes Boone.

  • 3 Takeaways From FDA Cell And Gene Therapy Draft Guidance

    Author Photo

    The U.S. Food and Drug Administration recently published draft guidance documents that sketch the clearest picture yet of the evolving regulatory framework for cell and gene therapies, reflecting an agency that is increasingly comfortable with flexible, science-driven approaches that extend beyond clinical trial models, say attorneys at MoFo.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.